To investigate the effects of CXCR4-antagonists in vitro, we used the following cell lines: SuDHL4 (as a GCB-DLBCL model), and RI-1 and U2932 (as a NGCB-DLBCL model). Here, CXCR4 is linked to diffuse large B-cell lymphoma.